Related Experiment Video
Updated: Dec 27, 2025

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
Published on: May 30, 2025
Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges
Rachel L Tomko1, Kevin M Gray1, Marilyn A Huestis2
1Department of Psychiatry and Behavioral Sciences, Medical university of South Carolina.
Purpose:
Cannabis abstinence traditionally is the primary outcome in cannabis use disorder (CUD) treatment trials. Due to the changing legality of cannabis, patient goals, and preliminary evidence that suggests individuals who reduce their cannabis use may show functional improvements, cannabis reduction is a desirable alternative outcome in CUD trials. We review challenges in measuring cannabis reduction and the evidence to support various definitions of reduction.
Findings:
Reduction in number of cannabis use days was associated with improvements in functioning across several studies. Reductions in quantity of cannabis used was inconsistently associated with improvements in functioning, though definitions of quantity varied across studies. Different biomarkers may be used depending on the reduction outcome.
Conclusions:
Biologically-confirmed reductions in frequency of cannabis use days may represent a viable endpoint in clinical trials for cannabis use disorder. Additional research is needed to better quantify reduction in cannabis amounts.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Measurement of Bioavailability: Pharmacodynamic Methods
Drug Concentrations: Measurements
Plasma...
Clinically Relevant Drug Product Specifications: Methods of Establishment
Longitudinal Research
Clinical Trials
There are four phases in a clinical trial. A phase one...

